Clinical Trial: A Single-Center, Prospective, Single-Arm Clinical Study of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for 3 Cycles in Resectable Stage II-IIIA NSCLC (China)

China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-Center, Prospective, Single-Arm Clinical Study of Serplulimab Combined with Chemotherapy as Neoadjuvant Therapy for 3 Cycles in Resectable Stage II-IIIA NSCLC'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133409

Registration Time: 2026/09/26

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Xi'an Jiaotong University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=325950

Published by HT Digital Content Services with permission from Health Daily Digest....